09:00 AM EDT, 06/12/2024 (MT Newswires) -- Avidity Biosciences ( RNA ) said Wednesday that initial data from an early-to-mid-stage study of its experimental drug, AOC 1020, to treat a rare muscle disease, facioscapulohumeral muscular dystrophy, showed a greater than 50% reduction in DUX4-regulated genes.

The company said it planned to accelerate the initiation of registrational cohorts in its early-to-mid study.

Avidity said AOC 1020 has also demonstrated favorable safety and tolerability, with all adverse events being mild or moderate.

Further, the company said it has identified delpacibart braxlosiran as the approved international nonproprietary name of AOC 1020, abbreviated as del-brax.

Shares of the company were up 22% in recent Wednesday premarket activity.

Price: 35.40, Change: +6.48, Percent Change: +22.41